Good mutant selectivity is therefore what affords EGFR kinase inhibitors such a wide therapeutic window in classical EGFR mutant NSCLC, allowing treatment with high enough doses that can be clinically effective while maintaining a tolerable safety profile for the patient. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.